Trial · NCT01874535
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
NCT01874535, Phase 4, Completed, Chang Gung Memorial Hospital; results first posted 2018-09-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy. Trials, record NCT01874535. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01874535
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
- NCT number
- NCT01874535
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 408 participants, actual
- Lead sponsor
- Chang Gung Memorial Hospital
- Conditions
- Erosive Esophagitis
- Interventions
- Esomeprazole 40 mg
- First posted
- 2013-06-11
- Last updated
- 2018-09-04
- Results first posted
- 2018-09-04
- Limitations and caveats
- The trial was performed in a single country
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Rates of Complete Symptom Relief | at the 20 weeks after the end of initial treatment. | Rate of complete symptom relief (CSR) at the end of initial treatment phase |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Rates of Complete Symptom Relief | at the 20 weeks after the end of initial treatment. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Rates of Complete Symptom Relief | 4 Week Group | 152 | participants | ||
| The Rates of Complete Symptom Relief | 8 Week Group | 157 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 4-week Group | 207 | |
| Overall Study | STARTED | 8-week Group | 201 | |
| Overall Study | COMPLETED | 4-week Group | 152 | |
| Overall Study | COMPLETED | 8-week Group | 157 | |
| Overall Study | NOT COMPLETED | 4-week Group | 55 | |
| Overall Study | NOT COMPLETED | 8-week Group | 44 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 4 Week Group | 0 | 207 |
| Total, all-cause mortality | 8 Week Group | 0 | 201 |
| Total, other adverse events | 4 Week Group | 0 | 207 |
| Total, other adverse events | 8 Week Group | 0 | 201 |
| Total, serious adverse events | 4 Week Group | 0 | 207 |
| Total, serious adverse events | 8 Week Group | 0 | 201 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25245625 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 4 Week Group vs 8 Week Group: The Rates of Complete Symptom Relief | Trial comparisons |
| 4 Week Group vs 8 Week Group: deaths from any cause | Trial comparisons |
| 4 Week Group vs 8 Week Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01874535
GET https://conductscience.org/api/trials/v1/NCT01874535/registered